FY2022 Earnings Forecast for Pear Therapeutics, Inc. Issued By Lifesci Capital (NASDAQ:PEAR)

Pear Therapeutics, Inc. (NASDAQ:PEARGet Rating) – Lifesci Capital increased their FY2022 earnings per share estimates for Pear Therapeutics in a research report issued on Tuesday, November 15th. Lifesci Capital analyst R. Rakhit now expects that the company will post earnings per share of ($0.80) for the year, up from their prior estimate of ($0.82). The consensus estimate for Pear Therapeutics’ current full-year earnings is ($0.82) per share. Lifesci Capital also issued estimates for Pear Therapeutics’ Q4 2022 earnings at ($0.16) EPS, Q1 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.09) EPS, FY2023 earnings at ($0.45) EPS, Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.04) EPS and FY2024 earnings at ($0.17) EPS.

Other equities research analysts have also recently issued reports about the company. Citigroup cut their target price on Pear Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday. BTIG Research cut their target price on Pear Therapeutics from $11.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, August 12th. Credit Suisse Group cut their target price on Pear Therapeutics from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Chardan Capital cut their target price on Pear Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Pear Therapeutics Stock Performance

PEAR stock opened at $1.88 on Friday. The stock has a market capitalization of $260.89 million, a price-to-earnings ratio of -8.55 and a beta of 0.93. Pear Therapeutics has a 1 year low of $1.34 and a 1 year high of $14.60. The stock’s fifty day moving average is $2.24 and its two-hundred day moving average is $2.41.

Insider Activity

In other news, major shareholder 5Am Partners Iv, Llc sold 311,160 shares of the firm’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $2.36, for a total transaction of $734,337.60. Following the transaction, the insider now directly owns 581,916 shares of the company’s stock, valued at $1,373,321.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have sold 995,150 shares of company stock valued at $2,112,352. Company insiders own 30.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PEAR. BlackRock Inc. grew its holdings in Pear Therapeutics by 603.2% during the third quarter. BlackRock Inc. now owns 3,014,890 shares of the company’s stock worth $6,151,000 after acquiring an additional 2,586,124 shares during the period. Vanguard Group Inc. grew its holdings in Pear Therapeutics by 203.0% during the third quarter. Vanguard Group Inc. now owns 3,226,467 shares of the company’s stock worth $6,581,000 after acquiring an additional 2,161,758 shares during the period. State Street Corp grew its holdings in Pear Therapeutics by 195.8% during the third quarter. State Street Corp now owns 923,012 shares of the company’s stock worth $1,883,000 after acquiring an additional 610,984 shares during the period. Millennium Management LLC grew its holdings in Pear Therapeutics by 574.1% during the second quarter. Millennium Management LLC now owns 248,399 shares of the company’s stock worth $383,000 after acquiring an additional 211,551 shares during the period. Finally, Darrow Company Inc. acquired a new position in Pear Therapeutics during the third quarter worth about $371,000. 55.39% of the stock is owned by institutional investors and hedge funds.

About Pear Therapeutics

(Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

Further Reading

Earnings History and Estimates for Pear Therapeutics (NASDAQ:PEAR)

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.